NCT00623116

A Study to Characterize Epidemiology, Clinical and Genetic Features of Kallmann Syndrome in Finland

Kallmann Syndrome in Finland

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: Hospital for Children and Adolescents, Finland · Academic / Other
• Sex: All
• Age: 15 Years
• Healthy volunteers: Accepted

Summary

Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Detailed description

Kallmann syndrome is comprised of idiopathic hypogonadotropic hypogonadism and anosmia (inability to smell). Associated phenotypes may include cryptorchidism, microphallus, bone deformations, mirror movements, hearing loss and infertility. Objective is to characterize epidemiology, clinical and genetic features of Kallmann syndrome in Finland.

Conditions

• Kallmann Syndrome

Interventions

Type	Name	Description
DRUG	Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)	clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.

Timeline

• Start date: 2007-12-01
• Primary completion: 2012-12-01
• Completion: 2025-12-01
• First posted: 2008-02-25
• Last updated: 2008-02-25

Locations

1 site across 1 country: Finland